Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Traumatic brain injury (TBI) remains a major global neurological concern, affecting millions of individuals each year and contributing substantially to long-term disability and mortality. Globally, nearly 37.9 million people are living with traumatic brain injury (TBI), with around 20.8 million new cases reported annually, reflecting a significant healthcare burden. Growing awareness of post-traumatic neurological complications has intensified research into targeted therapeutics and diagnostic innovations. According to traumatic brain injury (TBI) pipeline analysis by Expert Market Research, expanding clinical trials in neuroprotective agents, regenerative therapies, and biomarker-driven diagnostics are shaping future treatment strategies for this complex neurological condition.
-
Major companies involved in the traumatic brain injury (TBI) pipeline analysis include Asrogen, Hope Bioscience, and others.
-
Leading drugs currently in the pipeline include Somatropin and others.
-
Rising recognition of long-term neurological deficits following traumatic brain injury (TBI) is accelerating the development of targeted neuroregenerative and anti-inflammatory therapies. Growing clinical interest in stem-cell treatments, biomarker-guided diagnostics, and therapies targeting secondary brain injury pathways is expanding the pipeline, while increasing military and sports-related TBI cases are encouraging specialized therapeutic innovation.
Report Coverage
The Traumatic Brain Injury (TBI) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into traumatic brain injury (TBI) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Traumatic Brain Injury (TBI). The traumatic brain injury (TBI) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The traumatic brain injury (TBI) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with traumatic brain injury (TBI) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to traumatic brain injury (TBI).
Read more about this report - Request a Free Sample
Traumatic Brain Injury (TBI) Pipeline Outlook
The traumatic brain injury (TBI) pipeline outlook reflects increasing research efforts focused on improving diagnosis and developing targeted neuroprotective therapies.
Traumatic brain injury (TBI) treatment primarily involves supportive care, including intracranial pressure control, surgical intervention when necessary, rehabilitation, and symptomatic treatments addressing neurological complications. Advances in diagnostic technologies are also shaping the clinical landscape. For instance, in April 2025, the U.S. FDA cleared the EyeBOX system, a device designed to analyze eye-movement patterns to help identify concussion or mild traumatic brain injury (TBI). This technology provides objective neurological assessments, supporting faster clinical decision-making and improving diagnostic accuracy in emergency and sports-medicine settings.
Traumatic Brain Injury (TBI) Epidemiology
The epidemiology of traumatic brain injury (TBI) highlights its significant global health burden as one of the leading causes of death and disability. According to recent global analyses, approximately 37.9 million people were living with traumatic brain injury (TBI) worldwide in 2021, with about 20.8 million new cases reported annually. The global age-standardized prevalence rate is estimated at 448 cases per 100,000 population, while the incidence rate reaches 259 cases per 100,000 individuals. Major causes include road traffic accidents, falls, and violence. Despite improvements in prevention and trauma care, traumatic brain injury (TBI) continues to impose substantial long-term neurological and socioeconomic burdens worldwide.
Traumatic Brain Injury (TBI) – Pipeline Therapeutic Assessment
This section of the report covers the analysis of Traumatic Brain Injury (TBI) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The Traumatic Brain Injury (TBI) pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Traumatic Brain Injury (TBI) Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total Traumatic Brain Injury (TBI) clinical trials. Phase II accounts for the largest share of traumatic brain injury (TBI) clinical trials at 45%, followed by Phase I (23%), Phase III (20%), and Phase IV (8%). This distribution highlights strong mid-stage clinical activity, reflecting growing efforts to advance promising neuroprotective and regenerative therapies for traumatic brain injury management.
Traumatic Brain Injury (TBI) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the traumatic brain injury (TBI) pipeline analysis include monoclonal antibodies, small molecules, and gene therapies. The traumatic brain injury (TBI) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for traumatic brain injury (TBI). For instance, in March 2023, the FDA cleared a traumatic brain injury (TBI) blood test, i-STAT TBI Plasma Test, developed by Abbott Laboratories to aid clinicians in evaluating patients with suspected mild TBI. The diagnostic test measures specific biomarkers associated with brain injury, helping physicians determine whether CT imaging is necessary in emergency settings.
Traumatic Brain Injury (TBI) Clinical Trials – Key Players
The EMR report for the traumatic brain injury (TBI) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed traumatic brain injury (TBI) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Traumatic Brain Injury (TBI) clinical trials:
- SanBio
- Vasopharm GmbH
- Pinteon Therapeutics
- Asrogen
- Hope Biosciences
- CereMark Pharma
- Abalonex
- Supernus Pharmaceuticals
- Merz Pharmaceuticals GmbH
- NeuroTrauma Sciences
- Odyssey Group
Traumatic Brain Injury (TBI) – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Traumatic Brain Injury (TBI). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of traumatic brain injury (TBI) drug candidates.
Drug: Somatropin
Somatropin is a recombinant human growth hormone therapy that belongs to the endocrine hormone drug class and is widely produced by several pharmaceutical companies, including Pfizer and Novo Nordisk. In traumatic brain injury (TBI), somatropin is being explored to address growth hormone deficiency and metabolic dysfunction that can occur following brain trauma. The therapy works by stimulating insulin-like growth factor pathways that support tissue repair, neuroregeneration, and metabolic balance. Clinical research is evaluating its potential to improve neurological recovery and cognitive function after injury, with major pharmaceutical manufacturers supporting ongoing clinical investigation and therapeutic development efforts.
Biological: IPN10200
IPN10200 is an investigational botulinum toxin-based biologic therapy being developed by Ipsen for neuromuscular disorders associated with conditions such as traumatic brain injury (TBI). The biologic works by blocking acetylcholine release at neuromuscular junctions, thereby reducing excessive muscle contractions and relieving post-traumatic spasticity, a common complication of severe brain injury. By decreasing abnormal muscle activity, the therapy may help improve mobility, comfort, and functional recovery in affected patients. Ipsen, a global biopharmaceutical company known for its neurology and toxin-based therapeutics portfolio, is conducting clinical studies to evaluate the safety and therapeutic potential of IPN10200.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Traumatic Brain Injury (TBI) Pipeline Insight Report
- Which companies/institutions are leading the traumatic brain injury (TBI) drug development?
- Which company is leading the traumatic brain injury (TBI) pipeline development activities?
- What is the current traumatic brain injury (TBI) commercial assessment?
- What are the opportunities and challenges present in the traumatic brain injury (TBI) pipeline landscape?
- What is the efficacy and safety profile of traumatic brain injury (TBI) pipeline drugs?
- Which company is conducting major trials for traumatic brain injury (TBI) drugs?
- Which companies/institutions are involved in traumatic brain injury (TBI) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in traumatic brain injury (TBI)?
Reasons To Buy This Report
The Traumatic Brain Injury (TBI) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Traumatic Brain Injury (TBI). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into traumatic brain injury (TBI) collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Traumatic Brain Injury (TBI) (TBI) Epidemiology Forecast
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share